Search

Your search keyword '"Magrin, Luigi"' showing total 15 results
Start Over Author "Magrin, Luigi"
15 results on '"Magrin, Luigi"'

1. Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer

Author

Fanale, Daniele, Brando, Chiara, Corsini, Lidia Rita, Cutaia, Sofia, Di Donna, Mariano Catello, Randazzo, Ugo, Filorizzo, Clarissa, Lisanti, Chiara, Magrin, Luigi, Gurrera, Vittorio, Romano, Raffaella, Dimino, Alessandra, Bazan Russo, Tancredi Didier, Olive, Daniel, Vieni, Salvatore, Pantuso, Gianni, Giordano, Antonio, Chiantera, Vito, Russo, Antonio, Bazan, Viviana, and Iovanna, Juan Lucio

Published
2023
Full Text
View/download PDF

2. Clinical relevance of exosome-derived microRNAs in Ovarian Cancer: Looking for new tumor biological fingerprints

Author

Fanale, Daniele, Corsini, Lidia Rita, Bono, Marco, Randazzo, Ugo, Barraco, Nadia, Brando, Chiara, Cancelliere, Daniela, Contino, Silvia, Giurintano, Ambra, Magrin, Luigi, Pedone, Erika, Perez, Alessandro, Piraino, Paola, Pivetti, Alessia, Giovanni, Emilia Di, Russo, Tancredi Didier Bazan, Prestifilippo, Ornella, Gennusa, Vincenzo, Pantuso, Gianni, Russo, Antonio, and Bazan, Viviana

Published
2024
Full Text
View/download PDF

5. Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?

Author

Fanale, Daniele, Corsini, Lidia Rita, Scalia, Raimondo, Brando, Chiara, Cucinella, Alessandra, Madonia, Giorgio, Dimino, Alessandra, Filorizzo, Clarissa, Barraco, Nadia, Bono, Marco, Fiorino, Alessia, Magrin, Luigi, Sciacchitano, Roberta, Perez, Alessandro, Russo, Tancredi Didier Bazan, Pantuso, Gianni, Russo, Antonio, and Bazan, Viviana

Published
2022
Full Text
View/download PDF

7. Clinical relevance of exosome-derived microRNAs in Ovarian Cancer: looking for new tumor biological fingerprints

Author

Fanale, Daniele, primary, Corsini, Lidia Rita, additional, Bono, Marco, additional, Randazzo, Ugo, additional, Barraco, Nadia, additional, Brando, Chiara, additional, Cancelliere, Daniela, additional, Contino, Silvia, additional, Giurintano, Ambra, additional, Magrin, Luigi, additional, Pedone, Erika, additional, Perez, Alessandro, additional, Piraino, Paola, additional, Pivetti, Alessia, additional, Giovanni, Emilia Di, additional, Russo, Tancredi Didier Bazan, additional, Prestifilippo, Ornella, additional, Gennusa, Vincenzo, additional, Pantuso, Gianni, additional, Russo, Antonio, additional, and Bazan, Viviana, additional

Published
2023
Full Text
View/download PDF

8. Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab

Author

Incorvaia, Lorena, Dimino, Alessandra, Algeri, Laura, Brando, Chiara, Magrin, Luigi, De Luca, Ida, Pedone, Erika, Perez, Alessandro, Sciacchitano, Roberta, Bonasera, Annalisa, Bazan Russo, Tancredi Didier, Li Pomi, Federica, Peri, Marta, Gristina, Valerio, Galvano, Antonio, Giuffrida, Dario, Fazio, Ivan, Toia, Francesca, Cordova, Adriana, Florena, Ada Maria, Giordano, Antonio, Bazan, Viviana, Russo, Antonio, Badalamenti, Giuseppe, Incorvaia, Lorena, Dimino, Alessandra, Algeri, Laura, Brando, Chiara, Magrin, Luigi, De Luca, Ida, Pedone, Erika, Perez, Alessandro, Sciacchitano, Roberta, Bonasera, Annalisa, Bazan Russo, Tancredi Didier, Li Pomi, Federica, Peri, Marta, Gristina, Valerio, Galvano, Antonio, Giuffrida, Dario, Fazio, Ivan, Toia, Francesca, Cordova, Adriana, Florena, Ada Maria, Giordano, Antonio, Bazan, Viviana, Russo, Antonio, and Badalamenti, Giuseppe

Subjects
Cancer Research, predictive factors, Oncology, skin cancer non melanoma, avelumab, immunotherapy, body mass index - BMI, Merkel cell carcinoma (MCC)
Abstract

BackgroundMerkel cell carcinoma (MCC) is a rare and aggressive skin cancer, associated with a worse prognosis. The Immune Checkpoint Inhibitors (ICIs) avelumab and pembrolizumab have been recently approved as first-line treatment in metastatic MCC (mMCC). The clinical observation of improved outcomes in obese patients following treatment with ICIs, known as the “obesity paradox”, has been studied across many types of tumors. Probably due to the rarity of this tumor, data on mMMC patients are lacking.Patients and methodsThis is an observational, hospital-based, study to investigate the role of Body Mass Index (BMI) as predictive biomarker of ICI response in mMCC patients treated with avelumab as first-line treatment. The study population included the patients treated from February 2019 to October 2022 in an Italian referral center for rare tumors. Clinico-pathological characteristics, BMI, laboratory parameters (NLR and platelet count), and response to avelumab were analyzed from a MCC System database prospectively collected.ResultsThirty-two (32) patients were included. Notably, the presence of pre-treatment BMI ≥ 30 was significantly associated with longer PFS [BMI < 30 Group: median PFS, 4 months (95% CI: 2.5-5.4); BMI ≥ 30 Group: median PFS, not reached; pConclusionTo our knowledge, this is the first study that investigates the predictive role of BMI in MCC patients. Our data were consistent with the clinical observation of improved outcomes in obese patients across other tumor types. Thus, advanced age, a weakened immune system, and the obesity-associated “inflammaging”, are key factors that could impact the cancer immune responses of mMCC patients.

Published
2023

9. Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors

Author

Dimino, Alessandra, primary, Brando, Chiara, additional, Algeri, Laura, additional, Gristina, Valerio, additional, Pedone, Erika, additional, Peri, Marta, additional, Perez, Alessandro, additional, De Luca, Ida, additional, Sciacchitano, Roberta, additional, Magrin, Luigi, additional, Bazan Russo, Tancredi Didier, additional, Bono, Marco, additional, Barraco, Nadia, additional, Contino, Silvia, additional, La Mantia, Maria, additional, Galvano, Antonio, additional, Badalamenti, Giuseppe, additional, Russo, Antonio, additional, Bazan, Viviana, additional, and Incorvaia, Lorena, additional

Published
2022
Full Text
View/download PDF

10. Can circulating PD-1, PD-L1, BTN3A1, pan-BTN3As, BTN2A1 and BTLA levels enhance prognostic power of CA125 in patients with advanced high-grade serous ovarian cancer?

Author

Fanale, Daniele, primary, Corsini, Lidia Rita, additional, Brando, Chiara, additional, Cutaia, Sofia, additional, Di Donna, Mariano Catello, additional, Filorizzo, Clarissa, additional, Lisanti, Maria Chiara, additional, Randazzo, Ugo, additional, Magrin, Luigi, additional, Romano, Raffaella, additional, Bazan Russo, Tancredi Didier, additional, Olive, Daniel, additional, Vieni, Salvatore, additional, Pantuso, Gianni, additional, Chiantera, Vito, additional, Russo, Antonio, additional, Bazan, Viviana, additional, and Iovanna, Juan Lucio, additional

Published
2022
Full Text
View/download PDF

11. Prognostic and Predictive Role of Tumor-Infiltrating Lymphocytes (TILs) in Ovarian Cancer

Author

Fanale, Daniele, primary, Dimino, Alessandra, additional, Pedone, Erika, additional, Brando, Chiara, additional, Corsini, Lidia Rita, additional, Filorizzo, Clarissa, additional, Fiorino, Alessia, additional, Lisanti, Maria Chiara, additional, Magrin, Luigi, additional, Randazzo, Ugo, additional, Bazan Russo, Tancredi Didier, additional, Russo, Antonio, additional, and Bazan, Viviana, additional

Published
2022
Full Text
View/download PDF

12. Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors.

Author

Dimino, Alessandra, Brando, Chiara, Algeri, Laura, Gristina, Valerio, Pedone, Erika, Peri, Marta, Perez, Alessandro, De Luca, Ida, Sciacchitano, Roberta, Magrin, Luigi, Bazan Russo, Tancredi Didier, Bono, Marco, Barraco, Nadia, Contino, Silvia, La Mantia, Maria, Galvano, Antonio, Badalamenti, Giuseppe, Russo, Antonio, Bazan, Viviana, and Incorvaia, Lorena

Subjects
BIOMARKERS, GENETICS, GENETIC mutation, IMMUNE system, GASTROINTESTINAL tumors, GENE expression, TREATMENT effectiveness, PHENOTYPES, IMMUNOTHERAPY, SARCOMA
Abstract

Simple Summary: The effect of genetic alteration on the prognosis of patients affected by GIST has been extensively demonstrated. Unfortunately, not all GISTs could benefit from targeted therapies, underlining the need to deeply understand other predictive mechanisms. The link between immune checkpoints (especially PD-L1 expression), the tumor microenvironment, and the clinical behavior of GIST with different driver mutations is under investigation and represents an intriguing research field that could lead to improved prognostication in GIST. Gastrointestinal Stromal Tumors (GISTs) represent a paradigmatic model of oncogene addiction. Despite the well-known impact of the mutational status on clinical outcomes, we need to expand our knowledge to other factors that influence behavior heterogeneity in GIST patients. A growing body of studies has revealed that the tumor microenvironment (TME), mostly populated by tumor-associated macrophages (TAMs) and lymphocytes (TILs), and stromal differentiation (SD) have a significant impact on prognosis and response to treatment. Interestingly, even though the current knowledge of the role of immune response in this setting is still limited, recent pre-clinical and clinical data have highlighted the relevance of the TME in GISTs, with possible implications for clinical practice in the near future. Moreover, the expression of immune checkpoints, such as PD-L1, PD-1, and CTLA-4, and their relationship to the clinical phenotype in GIST are emerging as potential prognostic biomarkers. Looking forward, these variables related to the underlying tumoral microenvironment in GIST, though limited to still-ongoing trials, might lead to the potential use of immunotherapy, alone or in combination with targeted therapy, in advanced TKI-refractory GISTs. This review aims to deepen understanding of the potential link between mutational status and the immune microenvironment in GIST. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

13. Impact of Different Selection Approaches for Identifying Lynch Syndrome-Related Colorectal Cancer Patients: Unity Is Strength

Author

Fanale, Daniele, primary, Corsini, Lidia Rita, additional, Brando, Chiara, additional, Dimino, Alessandra, additional, Filorizzo, Clarissa, additional, Magrin, Luigi, additional, Sciacchitano, Roberta, additional, Fiorino, Alessia, additional, Bazan Russo, Tancredi Didier, additional, Calò, Valentina, additional, Iovanna, Juan Lucio, additional, Francini, Edoardo, additional, Russo, Antonio, additional, and Bazan, Viviana, additional

Published
2022
Full Text
View/download PDF

14. Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome

Author

Fanale, Daniele, primary, Fiorino, Alessia, additional, Incorvaia, Lorena, additional, Dimino, Alessandra, additional, Filorizzo, Clarissa, additional, Bono, Marco, additional, Cancelliere, Daniela, additional, Calò, Valentina, additional, Brando, Chiara, additional, Corsini, Lidia Rita, additional, Sciacchitano, Roberta, additional, Magrin, Luigi, additional, Pivetti, Alessia, additional, Pedone, Erika, additional, Madonia, Giorgio, additional, Cucinella, Alessandra, additional, Badalamenti, Giuseppe, additional, Russo, Antonio, additional, and Bazan, Viviana, additional

Published
2021
Full Text
View/download PDF

15. Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors

Author

Alessandra Dimino, Chiara Brando, Laura Algeri, Valerio Gristina, Erika Pedone, Marta Peri, Alessandro Perez, Ida De Luca, Roberta Sciacchitano, Luigi Magrin, Tancredi Didier Bazan Russo, Marco Bono, Nadia Barraco, Silvia Contino, Maria La Mantia, Antonio Galvano, Giuseppe Badalamenti, Antonio Russo, Viviana Bazan, Lorena Incorvaia, Dimino, Alessandra, Brando, Chiara, Algeri, Laura, Gristina, Valerio, Pedone, Erika, Peri, Marta, Perez, Alessandro, De Luca, Ida, Sciacchitano, Roberta, Magrin, Luigi, Bazan Russo, Tancredi Didier, Bono, Marco, Barraco, Nadia, Contino, Silvia, La Mantia, Maria, Galvano, Antonio, Badalamenti, Giuseppe, Russo, Antonio, Bazan, Viviana, and Incorvaia, Lorena

Subjects
Cancer Research, immune system, Oncology, target therapy, tumor microenvironment, immunotherapy, immune checkpoints, sarcomas, GIST
Abstract

Gastrointestinal Stromal Tumors (GISTs) represent a paradigmatic model of oncogene addiction. Despite the well-known impact of the mutational status on clinical outcomes, we need to expand our knowledge to other factors that influence behavior heterogeneity in GIST patients. A growing body of studies has revealed that the tumor microenvironment (TME), mostly populated by tumor-associated macrophages (TAMs) and lymphocytes (TILs), and stromal differentiation (SD) have a significant impact on prognosis and response to treatment. Interestingly, even though the current knowledge of the role of immune response in this setting is still limited, recent pre-clinical and clinical data have highlighted the relevance of the TME in GISTs, with possible implications for clinical practice in the near future. Moreover, the expression of immune checkpoints, such as PD-L1, PD-1, and CTLA-4, and their relationship to the clinical phenotype in GIST are emerging as potential prognostic biomarkers. Looking forward, these variables related to the underlying tumoral microenvironment in GIST, though limited to still-ongoing trials, might lead to the potential use of immunotherapy, alone or in combination with targeted therapy, in advanced TKI-refractory GISTs. This review aims to deepen understanding of the potential link between mutational status and the immune microenvironment in GIST.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results